Patients' perception about difficulty of treatment with trifluridine/tipiracil and pharmaceutical care: Effectiveness and safety
| Autor: | Rafael López, Elena López, Goretti Duran, Maria Francisca Vazquez, A. García, Cristina Gonzalez-Anleo, Manuel Touris, Bibiana Sanchez, María Jesús Lamas, Alicia Mosquera, Beatriz Bernardez, Marca Diaz, Alberto Llorente, Yolanda Vidal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 35:e18249-e18249 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e18249 Background: Trifluridine/tipiracil (TAS) is a new alternative in metastatic colorectal cancer patients (pts) previously treated with fluoropyrimidines, oxaliplatin and irinotecan. Objective:to analyze patients` perception about difficulty of dosage regimen with TAS, the effectiveness and safety. Methods: Retrospective observational study, including pts treated with TAS during expanded access in Spain. Oncology pharmacists, as integral part of cancer team, provide direct patient care medication therapy review, pharmacotherapy management, disease management, medication safety, dispense the medication and other clinical support that may lead to improved quality and clinical outcomes for cancer patient at the beginning of treatment with TAS. About perception we applied a survey with a numeric rating scale (0-10 integers) with 3 questions: difficulty of dosage at the beginning, at the end of 3rd cycle, and the relevance of the information provided by the oncology pharmacist. Variables studied: sex, age, KRAS status, treatment line, ECOG performance status (PS), dose reduction, previous chemotherapy and adverse events (AE) classified according to CTCAE v4.0. Effectiveness variable: progression-free survival (PFS). Results: 12 pts (10 men; 7 mutated KRAS) were included; median age 60.5 years (range 52-81). TAS line: 3rd line (4), ≥ 4th (8). PS 1 in 10 patients; 2 pts PS 2. Dose reduction was necessary in 41.7% pts. Currently 5 pts are still alive and in the survey they scored the dosage regimen with ≤5 points at the beginning and the same after 3 cycles. The relevance of, information provided by the oncology pharmacist was evaluated with 10 points. Effectiveness: median PFS 3.1 months (0.5-8.3), 2 pts continue on treatment ( medianfollow-up 8.1 months). Overall survival is not evaluable. Grade 3/4 hemotologic toxicities were most common (anemia 8,3%, neutropenia 25%). Conclusions: The perceived dosage difficulty is low, contrary to expectations. It is important to emphasize the evaluation of the information provided by the oncological pharmacist. Our study supports an effectiviness similar than the efficacy. Hematological is the most important and common toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|